2023-11-08 08:39:26
Date: November 08, 2023
Company name: Novel Biomedical (6810)
Subject: Novel biomedical product DNlite-IVD103 detection reagent, Thailand application name: DNlite-KT uPTM-FetA ELISA Kit (used to assess the risk of prognostic renal function failure in kidney transplant patients), has been issued an IVD marketing license by the Thai competent authority.
Spokesperson: Guo Zuxun
illustrate:
1. Date of occurrence: 112/11/08
2. Company name: Novel Biomedical Co., Ltd.
3. Relationship with the company (please enter the company or subsidiary): our company
4. Mutual shareholding ratio: Not applicable
5. Cause of occurrence: Our company received a notice today: The DNlite-IVD103 testing reagent applied for in Thailand.
Application name DNlite-KT uPTM-FetA ELISA Kit for assessing the prognosis of kidney transplant patients
The risk of renal failure has been confirmed by the Thai Food and Drug Administration,
Ministry of Public Heath) issues IVD marketing license.
6. Countermeasures: None
7. Other matters that should be stated (if the main system of the event or resolution is a company with public offering or above,
This material information also complies with the provisions of Article 7, Paragraph 9 of the Implementing Rules of the Securities and Exchange Act
Matters that have a significant impact on shareholders’ equity or securities prices):
(1) Obtaining a Thai listing license will be beneficial to the local sales of our company’s products.
(2) The company belongs to the biotechnology industry. For the company’s financial and revenue information, please refer to the public observatory information.
Investors are advised to exercise prudent judgment and invest cautiously.
1699529082
#AnnouncementThe #biomedical #product #DNliteIVD103 #detection #reagent #Thailands #application #DNliteKT #uPTMFetA #ELISA #Kit #assess #risk #prognostic #renal #failure #kidney #transplant #patients #approved #Thai #competent #authority #IVD #approval